Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma
NCT ID: NCT01305122
Last Updated: 2021-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
112 participants
INTERVENTIONAL
2011-02-28
2018-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy)
* cohort B: patients with disease simple monitoring.
The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
NCT06036706
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
NCT01417507
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
NCT04461002
Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
NCT06610851
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
NCT00967200
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OMS grade II glioma
neurocognitive tests
neurocognitive tests
* inclusion
* 1 year
* 3 years
* 5 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
neurocognitive tests
* inclusion
* 1 year
* 3 years
* 5 years
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed informed consent
* age \>=18
* IK \>=80%
* ability to read, write and undertand French
Exclusion Criteria
* other neurologic or psychiatric disease
* history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization
* neuroleptic concomitant treatment
* pregnant or lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, France
OTHER_GOV
Centre Leon Berard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Pierre SUNYACH, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Léon Bérard, Lyon - FRANCE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH Amiens-Picardie
Amiens, , France
Institut de Cancérologie de l'Ouest
Angers, , France
Hôpital Jean Minjoz
Besançon, , France
Hôpital Saint André
Bordeaux, , France
Centre Georges François Leclerc
Dijon, , France
Centre Oscar Lambret
Lille, , France
CHRU de Lille
Lille, , France
Hôpital d'instruction des armées Desgenettes
Lyon, , France
Centre Léon Bérard
Lyon, , France
Hôpital Guy de Chauliac
Montpellier, , France
Hôpital Central de Nancy
Nancy, , France
Hôpital Pasteur
Nice, , France
Centre Antoine Lacassagne
Nice, , France
Hôpital Pitié Salpêtrière
Paris, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Hôpital Maison Blanche
Reims, , France
CHU Charles NICOLLE
Rouen, , France
Centre Henri Becquerel
Rouen, , France
Centre René Gauducheau
Saint-Herblain, , France
CH Valenciennes
Valenciennes, , France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TUMEURS GLIALES
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.